A Modular Polymer Enhancer Promotes AAV Transduction and Circumvents Preexisting Immunity in Nonhuman Primates
Human Gene Therapy · 29.07.2026
DOI: 10.1177/10430342261471124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, online erschienen am 29.07.2026. Verfasst von Lauren E Switala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio, USA. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Division of Intramural Research, Wake Forest Clinical and Translational Science Award, NIH Office of the Director.
Abstract (Originalsprache)
Adeno-associated virus (AAV) gene therapy is frequently hindered by dose-limiting toxicities and preexisting neutralizing antibodies (nAbs). Here, we evaluate enhancer polymer (ePL), a cargo-less poly(L-lactic-co-glycolic acid) nanoparticle, the systemic administration of which demonstrated biocompatibility in nonhuman primates (NHPs) and generated a protransduction serum secretome that significantly enhanced AAV uptake in human iPSC-derived cardiomyocytes. Proteomic analysis of human peripheral blood mononuclear cell-derived secretomes identified a transient upregulation of AAV-entry factors, including ITGB3, alongside a downregulation of inflammatory cytokine pathways. Mechanistically, ePL-stimulated macrophages release a paracrine secretome that triggers the rapid, transient degradation of hepatic insulin receptor substrate 2 and subsequent AKT inhibition in liver and isolated primary mouse hepatocytes. Additionally, ePL attenuated the levels of NHP-derived nAbs in vitro and in a mouse-NHP xenotransfusion model without depleting total systemic immunoglobulins. Finally, ePL reduced Immunoglobulin G (IgG) secretory capacity of splenic B cells, suggesting a mechanistic link by which levels of nAbs are likely attenuated. Together, these findings highlight ePL as a promising supporting agent to improve AAV gene transfer, warranting its further optimization for clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio, USA.
- Department of Biomedical Engineering, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio, USA.
- Cardiovascular Research Institute, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio, USA.
- The Blood, Heart, Lung, and Immunology Research Center, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio, USA.
- Department of Pharmacology, Case Western Reserve University School of Medicine and University Hospitals, Cleveland, Ohio, USA.
- Comparative Medicine, Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
ORCID-Profile: Afsana Mim Khandaker, Andrei Maiseyeu
Förderung
- Division of Intramural Research
- Wake Forest Clinical and Translational Science Award
- NIH Office of the Director
- The Council to Advance Human Health
Zitieren
APA
Switala, L. E., Khandaker, A. M., Dutta, S., Jorgensen, M. J., & Maiseyeu, A. (2026). A Modular Polymer Enhancer Promotes AAV Transduction and Circumvents Preexisting Immunity in Nonhuman Primates. Human Gene Therapy. https://doi.org/10.1177/10430342261471124
Vancouver
Switala LE, Khandaker AM, Dutta S, Jorgensen MJ, Maiseyeu A. A Modular Polymer Enhancer Promotes AAV Transduction and Circumvents Preexisting Immunity in Nonhuman Primates. Human Gene Therapy. 2026. doi:10.1177/10430342261471124
BibTeX
@article{Switala2026,
author = {Switala, Lauren E and Khandaker, Afsana Mim and Dutta, Sumita and Jorgensen, Matthew J and Maiseyeu, Andrei},
title = {A Modular Polymer Enhancer Promotes AAV Transduction and Circumvents Preexisting Immunity in Nonhuman Primates},
journal = {Human Gene Therapy},
year = {2026},
doi = {10.1177/10430342261471124}
}
EUVIMED